Gilead Sciences continues to battle challenges in the HCV market, but its HIV product sales grew nicely in the third quarter. Management remains optimistic regarding the potential of its cell therapy treatment, headlined by Yescarta.
This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!